Çelik, İrem Nur

Profile Picture
Name Variants
Çelik, İrem Nur
Çelik,İ.N.
İrem Nur, Çelik
Ç.,İrem Nur
Celik, Irem Nur
İ.,Çelik
I., Celik
C.,Irem Nur
C., Irem Nur
I.N.Celik
İ.N.Çelik
Celik,I.N.
Irem Nur, Celik
Çelik,İ.
Job Title
Öğretim Görevlisi
Email Address
irem.celik@atilim.edu.tr
Main Affiliation
Operating Room Services Program
Status
Former Staff
Website
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID

Sustainable Development Goals Report Points

SDG data could not be loaded because of an error. Please refresh the page or try again later.
Scholarly Output

1

Articles

1

Citation Count

2

Supervised Theses

0

Filters

20211
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Article
    Citation - Scopus: 5
    Real-World Data From Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
    (AVES, 2021) Demirtürk,N.; Aygen,B.; Çelik,İ.; Mıstık,R.; Akhan,S.; Barut,Ş.; Doğan,N.; Operating Room Services Program
    Background: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice. Methods: Data from patients with chronic hepatitis C treated with SOF/LDV ± RBV or SOF/RBV in 31 centers across Turkey between April 1, 2017, and August 31, 2018, were recorded in a nationwide database among infectious disease specialists. Demographics, clinical, and virological outcomes were analyzed. Results: A total of 552 patients were included in the study. The mean age of the patients was 51.28 ± 14.2, and 293 (55.8%) were female. The majority had HCV genotype 1b infection (65%), 75.04% of the patients underwent treatment, and non-cirrhosis was present at baseline in 381 patients (72.6%). SOF/LDV ± RBV treatment was given to 477 patients and 48 patients received SOF/RBV according to HCV genotype. The total SVR12 rate was 99% in all patients. Five patients experienced disease relapse during the study and all of them were genotype 2. In patients infected with HCV GT2, SVR12 was 77.3%. SVR was 100% in all patients infected with other HCV genotypes. All treatments were well tolerated by patients without causing severe adverse events. Side effects and side effects-associated treatment discontinuation rates were 28.2% and 0.4%, respectively. Weakness (13.7%) was the common side effect. Conclusion: The present real-world data of 525 patients with HCV genotypes 1, 1a, 1b, 3, 4, and 5 who underwent SOF/LDV ± RBV treatment in Turkey demonstrated a high efficacy and safety profile. HCV GT2 patients should be treated with more efficacious treatment. © Copyright 2021 by The Turkish Society of Gastroenterology • Available online at turkjgastroenterol.org